Efficacy of sotrovimab versus molnupiravir in preventing severe COVID-19 outcomes in non-hospitalized high-risk COVID-19 adult patients
In a recent study published on the medRxiv * prepress server, researchers compared the effectiveness of sotrovimab [an intravenously administered neutralizing monoclonal antibody (nMAb)] and molnupiravir (an orally administered antiviral drug) to prevent the serious outcomes of coronavirus 2019 (COVID-19) among non-hospitalized and high-risk patients with COVID-19 across England. Study: Comparative efficacy of sotrovimab and …